Opinion|Videos|October 15, 2026
Cardioembolic Stroke Severity: Disability, Mortality, and Recurrence Risk in AFib
Author(s)Geoffrey D. Barnes, MD, MSc
Cardioembolic stroke produces more severe strokes, greater disability, higher mortality, and frequent recurrence than other subtypes. Dr. Barnes reviews the outcome data that make prevention a clinical priority.
Advertisement
This episode, "Cardioembolic Stroke Severity: Disability, Mortality, and Recurrence Risk in AFib," features Dr. Barnes examining the outcome data behind the severity of this stroke subtype.
Dr. Barnes explains that cardioembolic stroke is the most severe stroke subtype, and he supports that claim with specific outcome data. Patients who experience this type of stroke have a significantly higher risk of very severe stroke. He defines that as a score above 20 on the NIH Stroke Severity Score. Very severe stroke is about five times more common with cardioembolic stroke than with other stroke types.
Dr. Barnes also points to worse functional outcomes. Favorable disability status, meaning patients who have minimal deficits after the stroke, is less common after a cardioembolic event. Roughly half of these patients still live with disability at three months. For the other stroke subtypes, only about a third of patients have disability at that point.
He then turns to mortality, which he says clinicians must worry about alongside disability. Death is about four to four and a half times more common after a cardioembolic stroke than after a non-cardioembolic stroke. One-year mortality rates are around 40 to 45 percent. Five-year mortality rates are higher still, at roughly 65 to 80 percent.
Dr. Barnes adds that survival does not end the risk. Even patients who survive the first stroke, and who avoid significant disability, remain vulnerable to a second event. He cites recurrence rates of roughly 25 percent at five years for cardioembolic stroke.
He concludes that cardioembolic stroke is a highly morbid and highly mortal condition. Taken together, the severity scores, disability rates, mortality figures, and recurrence risk show why identifying and preventing this subtype deserves clinical priority.
Our next episode, "Cardioembolic Stroke Costs in AFib: Hospitalization, Disability, and Comorbidities," turns to the hospital and long-term costs that follow these severe strokes.
Advertisement
Related to this article
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Non-CF Bronchiectasis Linked to High Medicare Use and Spending
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
5